Highmark Health names ex-UnitedHealth exec as COO
Heather Cianfrocco is joining the Pittsburgh-based healthcare company as its COO effective immediately.
Highmark Health names ex-UnitedHealth exec as COO Read More »
Heather Cianfrocco is joining the Pittsburgh-based healthcare company as its COO effective immediately.
Highmark Health names ex-UnitedHealth exec as COO Read More »
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
Pfizer is a 2029 story but Q126 lays foundation for growth Read More »
Mistras, who joins the heart valve company following two years as CFO at pharmaceutical firm Viatris, also brings investment banking experience to the role.
Un reciente estudio ha permitido desentrañar los fascinantes detalles de un singular ecosistema formado en torno a una emanación de gases a 2,5 kilómetros de profundidad, cerca de la costa de Antofagasta, Chile. Este entorno submarino alberga una amplia diversidad de microorgani …
The neurostimulation device company intends to offer 10 million shares for between $14 and $16 each.
El cerdo extinto Cainochoerus vivió en el este de África durante el Mioceno, hace unos 6 millones de años, y era mucho más pequeño que los cerdos africanos actuales. Ahora, un equipo de investigación en paleontología ha descubierto mandíbulas y …
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs Read More »
Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead Read More »
WakeMed would become part of Advocate Health, Atrium’s parent company. The deal has sparked concern from local lawmakers, who worry it could raise healthcare prices in North Carolina’s most populous county.
Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.
Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat Read More »